Provided by Tiger Fintech (Singapore) Pte. Ltd.

Qudian Inc.

4.82
-0.0900-1.83%
Volume:19.05K
Turnover:92.26K
Market Cap:795.91M
PE:11.42
High:4.86
Open:4.84
Low:4.82
Close:4.91
52wk High:5.08
52wk Low:2.04
Shares:165.13M
Float Shares:96.72M
Volume Ratio:0.65
T/O Rate:0.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4223
EPS(LYR):0.0687
ROE:4.58%
ROA:-1.68%
PB:0.49
PE(LYR):70.13

Loading ...

QD Laser Sees Parent FY Loss Y445.00M

Dow Jones
·
Nov 13

Stock Track | Qudian Inc. Stock Soars 5.14% Following Announcement of Name and Ticker Symbol Change

Stock Track
·
Nov 13

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

GlobeNewswire
·
Nov 12

Qudian Inc. Shareholders to Vote on Company Name and Ticker Symbol Change at Upcoming EGM

Reuters
·
Nov 12

Qudian board approves name change to High Templar Tech, symbol change

TIPRANKS
·
Nov 12

Qudian Inc - to Change Name to High Templar Tech Limited

THOMSON REUTERS
·
Nov 12

Qudian Inc. Announces Board Approval of Changes to Company Name and Ticker Symbol, as Well as Calling of Extraordinary General Meeting

THOMSON REUTERS
·
Nov 12

Qudian Inc - to Change Ticker Symbol to Htt

THOMSON REUTERS
·
Nov 12

AOC Launches New 24-inch Monitor at 649 Yuan: FHD 260Hz Screen with QD Quantum Dot Technology

Deep News
·
Nov 04

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

GlobeNewswire
·
Oct 22

2025 OCP Global Summit: Supernodes and "Scale Up" Take Center Stage

Deep News
·
Oct 22

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

GlobeNewswire
·
Oct 08

Why Is Arcus Biosciences Stock Trading Higher On Monday?

Benzinga_recent_news
·
Oct 07

LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms

GlobeNewswire
·
Oct 06

Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension

GlobeNewswire
·
Sep 30

BRIEF-Qudian Announces Changes To Board Of Directors

Reuters
·
Sep 24

Qudian Inc. Announces Board of Directors Resignation as Mr. Yingming Li Steps Down

Reuters
·
Sep 24

Qudian Inc. Announces Changes to Board of Directors

THOMSON REUTERS
·
Sep 24

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewswire
·
Sep 11

Stock Track | Qudian Inc. Shares Plummet 5.07% Despite Financial Improvements, Operational Challenges Persist

Stock Track
·
Sep 05